Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers.
about
Exercise as an Adjuvant Therapy for Hematopoietic Stem Cell MobilizationA glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study.Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment.Towards Quantitative Systems Pharmacology Models of Chemotherapy-Induced Neutropenia.Modelling chemotherapy effects on granulopoiesis.Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans.Development of biosimilars--pharmacokinetic and pharmacodynamic considerations.Pharmacokinetics and pharmacodynamics of pegfilgrastim.Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.A cell-level model of pharmacodynamics-mediated drug disposition.An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males.Understanding, treating and avoiding hematological disease: better medicine through mathematics?An upper bound for the half-removal time of neutrophils from circulation.Development of a new G-CSF product based on biosimilarity assessment.Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations.A Mathematical Model of Granulopoiesis Incorporating the Negative Feedback Dynamics and Kinetics of G-CSF/Neutrophil Binding and Internalization.Steady-state volume of distribution of two-compartment models with simultaneous linear and saturated elimination.Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.
P2860
Q26749247-2A4BF451-8BC3-4356-AFD3-9C829EC1DF6BQ33403643-ECE9D64D-FC75-46DF-8064-DB5A22820D90Q33431320-EC8F73B9-75F7-416D-830A-E670552D1F6DQ33712928-300FA6E4-6794-4E36-BA6B-80568054EB61Q33729784-223B277D-7C41-419F-86B1-6E8663C8ED08Q34996295-1C57CAA9-DCAC-43DF-B6A2-33355103245FQ36427261-31D90449-F308-4F83-8F70-544563BB1C4FQ37676066-26700FCB-5F4F-4BEC-AE46-28A2595CEF6DQ37860299-8BE0F253-04C2-4C40-B907-43963CC6C847Q38072290-709EB228-D365-4158-B1A5-FBC004A7DBB8Q39406092-7739975A-BFDE-4BC3-9AED-0F2FB3A5FA85Q40985752-9E661CA8-2C62-42D5-980F-BA10279AE0A6Q41742420-C3137A8D-7735-461C-91AB-54F86DF93A22Q42383007-506D5D0A-0C1D-4D04-9426-9BCB69ED59FAQ42643304-3302EB4A-3705-46A7-9F17-56F683E14515Q42689963-8CF29DD2-A166-4E50-AC5D-E21975E3273DQ43635728-B820052B-3BBC-4E5C-A077-661A61F9A0D5Q50561543-5194F3C5-0886-4108-8B8A-0803F124FCF8Q50611519-AF33FE27-1C64-44D5-A414-048284BA7654Q50878372-835FF1ED-04B9-4FFA-980A-B53B6722AF8C
P2860
Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Population pharmacokinetic-pha ...... uG-CSF) in healthy volunteers.
@en
Population pharmacokinetic-pharmacodynamic modeling of filgrastim
@nl
type
label
Population pharmacokinetic-pha ...... uG-CSF) in healthy volunteers.
@en
Population pharmacokinetic-pharmacodynamic modeling of filgrastim
@nl
prefLabel
Population pharmacokinetic-pha ...... uG-CSF) in healthy volunteers.
@en
Population pharmacokinetic-pharmacodynamic modeling of filgrastim
@nl
P2093
P356
P1476
Population pharmacokinetic-pha ...... uG-CSF) in healthy volunteers.
@en
P2093
P2888
P304
P356
10.1023/A:1011534529622
P577
2001-08-01T00:00:00Z
P6179
1006283462